可生物降解直肠周围间隔物能否减轻局限性前列腺癌放疗中的治疗毒性——系统综述与荟萃分析
间隔物使用与晚期(1.62% vs. 9.35%,RR=0.25,95%CI=0.15-0.42,P<0.001)和早期2级及以上直肠毒性(3.07% vs. 6.05%,RR=0.53,95%CI=0.33-0.86,P<0.001)风险降低相关,未观察到3级及以上胃肠道事件差异,肠道、泌尿及性功能生活质量无统计学差异。
要点
- 间隔物组晚期直肠毒性1.62% vs 无间隔物组9.35%(RR=0.25,95%CI=0.15-0.42,P<0.001)。
- 间隔物组早期2级及以上直肠毒性3.07% vs 无间隔物组6.05%(RR=0.53,95%CI=0.33-0.86,P<0.001)。
- 3级及以上胃肠道事件及肠道、泌尿、性功能生活质量无统计学差异。
核心结论
- 在局限性前列腺癌放疗患者中,使用直肠周围间隔物与直肠毒性降低相关。
研究设计与样本
- 2024年3月对MEDLINE、Embase和Cochrane Central Register of controlled trials进行系统检索,纳入2010年以来发表的前瞻性和回顾性比较研究。
- 采用随机效应荟萃分析,使用加权均数差,结局以二分类形式报告。
主要发现
- 间隔物组晚期直肠毒性1.62% vs 无间隔物组9.35%(RR=0.25,95%CI=0.15-0.42,P<0.001)。
- 间隔物组早期2级及以上直肠毒性3.07% vs 无间隔物组6.05%(RR=0.53,95%CI=0.33-0.86,P<0.001)。
- 3级及以上胃肠道事件(急性或晚期)无差异。
- 肠道相关生活质量无统计学差异(风险差=-0.16,95%CI=-0.38-0.06,P=0.15)。
- 直肠周围间隔物对泌尿或性功能生活质量领域无负面影响。
关键数值与推荐
- 早期(≤3个月)和晚期直肠毒性按常见不良事件评价标准(CTCAE)分层评估。
- 评估肠道、性功能和泌尿领域生活质量的最小临床重要差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: There is an increasing use of biodegradable peri-rectal spacer prior to radiation therapy for prostate cancer to reduce treatment-associated rectal toxicity. While data from individual trials and cohorts is maturing, there is a lack of an updated quantitative analysis that includes outcomes following peri-rectal spacer. We aim to delineate the clinical impact of peri-rectal spacer in localised prostate cancer patients treated with radiotherapy. METHODS: In March 2024, a systematic search was performed on MEDLINE, Embase, and Cochrane Central Register of controlled trials for publications since the year 2010. Prospective and retrospective studies reporting comparative outcomes of patients with and without peri-rectal spacer prior to radiotherapy were considered. Outcomes are reported in binary fashion. Random effect meta-analysis with the use of weighted mean difference was adopted. Early (≤3 months) and late rectal toxicity stratified according to the Common Terminology Criteria for Adverse Events (CTCAE) criteria, early and late genitourinary toxicity, quality of life in bowel, sexual and urinary domains (in terms of minimal clinically important difference) were assessed. RESULTS: The systematic review included 17 studies. There are 3 RCTs, 3 prospective cohorts, and 11 retrospective cohorts. Three thousand two hundred patients were included, with 1471 patients who received peri-rectal spacer and 1729 without. The use of spacer is associated with lower likelihood of late (1.62% vs. 9.35%, RR = 0.25, 95% CI = 0.15-0.42, P < 0.001) and early grade 2 or above late rectal toxicity (3.07% vs. 6.05%, RR = 0.53, 95% CI = 0.33-0.86, P < 0.001). No difference is observed in significant grade 3 or above GI (acute or late) events. There is no statistical difference in bowel-related bowel QoL (risk difference = -0.16, 95% CI = -0.38-0.06, P = 0.15). The perirectal spacer is not associated with negative impact to urinary or sexual domains of QoL either. CONCLUSION: In localised prostate cancer patients treated with radiation therapy, the use of peri-rectal spacer is associated with reduced rectal toxicities.
引用
- Wong CH, Ko IC, Leung DK, et al. Does biodegradable peri-rectal spacer mitigate treatment toxicities in radiation therapy for localised prostate cancer-a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2025. PMID: 40148672. doi:10.1038/s41391-025-00961-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。